Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and dostarlimab in recurrent or progressive cervix cancer
NCT04068753Phase 2Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Feb 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and dostarlimab in Cervical Cancer (CC), sponsored by University of Oklahoma. Primary endpoint: Objective Response Rate at 1 year. Started Feb 2020; status: active, not recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04068753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068753.